Thoracic FDG PET: State of the art

被引:37
作者
Erasmus, JJ [1 ]
McAdams, HP [1 ]
Patz, EF [1 ]
Goodman, PC [1 ]
Coleman, RE [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA
关键词
lung neoplasms; diagnosis; emission CT (ECT); radionuclide studies; staging;
D O I
10.1148/radiographics.18.1.9460106
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The D-glucose analogue 2-(fluorine-18) fluoro-2-deoxy-D-glucose (FDG) is the most commonly used radionuclide in positron emission tomography (PET) of the thorax. Increased glucose metabolism by malignant cells allows physiologic differentiation between benign and malignant abnormalities. FDG PET is consequently useful in characterizing indeterminate pulmonary nodules and in staging and assessing the response to treatment of lung cancer. FDG PET is accurate in classification of indeterminate pulmonary nodules as benign. Nodules with low FDG uptake are followed up radiographically; nodules with increased FDG uptake should be evaluated with biopsy or resected. In the staging of lung cancer, FDG PET is useful in evaluating local disease and pleural and chest wall involvement. The accuracy of FDG PET in demonstrating intrathoracic metastatic nodal disease is greater than that of computed tomography or magnetic resonance imaging. Whole-body PET is useful in detection of extrathoracic metastases. Conventional imaging often does not allow differentiation of tumor from posttreatment scarring. Increased FDG uptake at the sites of residual radiographic abnormalities is indicative of persistent or recurrent tumor.
引用
收藏
页码:5 / 20
页数:16
相关论文
共 40 条
[11]   DIFFERENTIATION OF RESIDUAL OR RECURRENT TUMORS FROM POSTTREATMENT CHANGES WITH F-18 FDG PET [J].
KIM, EE ;
CHUNG, SK ;
HAYNIE, TP ;
KIM, CG ;
CHO, BJ ;
PODOLOFF, DA ;
TILBURY, RS ;
YANG, DJ ;
YUNG, WKA ;
MOSER, RP ;
AJANI, JA .
RADIOGRAPHICS, 1992, 12 (02) :269-279
[12]   THE RADIOLOGIC STAGING OF LUNG-CANCER [J].
KLEIN, JS ;
WEBB, WR .
JOURNAL OF THORACIC IMAGING, 1991, 7 (01) :29-47
[13]  
KUBOTA K, 1990, J NUCL MED, V31, P1927
[14]   POSITRON EMISSION TOMOGRAPHY FOR TREATMENT EVALUATION AND RECURRENCE DETECTION COMPARED WITH CT IN LONG-TERM FOLLOW-UP CASES OF LUNG-CANCER [J].
KUBOTA, K ;
YAMADA, S ;
ISHIWATA, K ;
ITO, M ;
IDO, T .
CLINICAL NUCLEAR MEDICINE, 1992, 17 (11) :877-881
[15]  
LANGEN KJ, 1993, J NUCL MED, V34, P355
[16]   WHOLE-BODY F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN PREOPERATIVE EVALUATION OF LUNG-CANCER [J].
LEWIS, P ;
GRIFFIN, S ;
MARSDEN, P ;
GEE, T ;
NUNAN, T ;
MALSEY, M ;
DUSSEK, J .
LANCET, 1994, 344 (8932) :1265-1266
[17]  
LINDHOLM P, 1993, J NUCL MED, V34, P1
[18]   CLINICAL STAGING OF PATIENTS WITH NON-SMALL-CELL LUNG-CANCER [J].
LITTLE, AG ;
STITIK, FP .
CHEST, 1990, 97 (06) :1431-1438
[19]  
LOWE VJ, 1994, J NUCL MED, V35, P1771
[20]  
MARTINI N, 1985, J THORAC CARDIOV SUR, V90, P639